Transaction #34275 · Form 4 · 0001701247-26-000014
Enliven Therapeutics, Inc. · Exercise / conversion · Common Stock
Enliven Therapeutics, Inc. · Transacted October 19, 2026 · Filed October 21, 2026
What does this filing report?
An SEC Form 4 filing for Enliven Therapeutics, Inc. records an exercise / conversion involving Common Stock on October 19, 2026. The reported quantity was 5,000. The filing date is October 21, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Enliven Therapeutics, Inc.
- Company CIK
- 0001672619
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 5,000
- Reported price
- 2.48
- Reference value
- 12,400
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 30,000
- Ownership description
- Not reported
- SEC acceptance time
- Oct 21, 2026, 5:51 PM EDT
- 10b5-1 indication
- Indicated in filing
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Collins Helen Louise ↗
CHIEF MEDICAL OFFICER
CIK 0001701247
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.
- F2
- Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
- F3
- This transaction was executed in multiple trades at prices ranging from $37.785 to $38.75. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F4
- These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
- F5
- All of the shares subject to this option are fully vested and exercisable as of the date hereof.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.